Current Investigations
Securities Fraud
Governance & Derivative
Mergers & Acquisitions
Final Approval of $27.5 Million Settlement Granted in Aimmune Merger Litigation
After more than four years of litigation, the Hon. Maxine Chesney entered a Final Judgment approving a $27.5 million settlement for the Class in a Class action against Aimmune Therapeutics.
Who We Are
An introduction to Kahn Swick & Foti (KSF), widely regarded as the leading boutique law firm for securities litigation representing institutional investors around the world.
Our Successes
An overview of KSF’s landmark results, including record-breaking class action settlements and billions recovered for institutional clients through strategic, high-stakes litigation.
Our Services
A breakdown of KSF’s core services—class actions, derivative suits, loss analysis, and 1st Response monitoring—all delivered on a no-recovery, no-fee basis to protect investor capital.
Your Responsibility
A discussion on fiduciary duties and why stepping forward as lead plaintiff can enhance recoveries, influence litigation, and fulfill trust and oversight obligations.